The effects of ingestion time of gliclazide in relationship to meals on plasma glucose, insulin and C-peptide levels.
The effect of altering the timing of gliclazide administration in relation to a meal was studied in ten type 2 (non-insulin dependent) chronically treated diabetics. Gliclazide was given 30 min before, at the start of and 30 min after breakfast or omitted altogether. Plasma gliclazide was present at greater than 2 mg/l throughout the study periods. Administration at 30 min after the meal significantly delayed the time to peak for plasma gliclazide. No significant difference was noted in plasma glucose, insulin or c-peptide patterns with any protocol. It is concluded that, in clinical practice, with chronically treated diabetics the timing of gliclazide ingestion in relation to meals is not critical.
Batch
J
J
Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Australia.
Ma
A
A
Bird
D
D
Noble
R
R
Charles
B
B
Ravenscroft
P
P
Cameron
D
D
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D005260:Female; D005502:Food; D005907:Gliclazide / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000494:pharmacology*; D013997:Time Factors
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013453:Sulfonylurea Compounds; D005907:Gliclazide